ANI Pharmaceuticals, Inc. — 2020 Form 10-K
Business context and reporting period. ANI is an integrated specialty pharmaceutical company developing, manufacturing, and marketing generic and branded prescription drugs, with contract development and manufacturing operations. This annual report covers the fiscal year ended December 31, 2020; quarterly data are also provided. ANI operated three manufacturing facilities and reported one business segment.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Net revenue | $208.5 million | $206.5 million |
| Operating income (loss) | $(16.0) million | $16.4 million |
| Net income (loss) | $(22.5) million | $6.1 million |
| Diluted EPS | $(1.88) | $0.50 |
| Cash from operations | $15.3 million | $45.6 million |
| Cash used in investing | $(68.3) million | $(27.5) million |
- Revenue increased 0.9%. Generic product revenue rose 14.4% to $147.3 million, while branded product revenue fell 24.8% to $48.0 million and contract manufacturing revenue declined 17.2% to $9.2 million.
- Cost of sales, excluding depreciation and amortization, rose 38.0% to $87.2 million; reported as a share of revenue, it increased to 41.8% from 30.6%. Operating margin fell to negative 7.7% from 8.0%; net margin was negative 10.8% versus positive 3.0%.
- Operating expenses included $11.3 million of Cortrophin pre-launch charges, up from $6.7 million; $5.6 million of inventory reserve charges; and $6.5 million in expenses related to the former CEO’s departure. Interest expense declined to $9.5 million from $13.0 million, primarily because 2019 included convertible-debt discount amortization.
- Cash and cash equivalents were $7.9 million at year-end, down from $62.3 million; a separate $5.0 million was restricted cash. Current assets were $170.3 million and current liabilities $78.6 million, with a reported working-capital ratio of 2.2.
- Outstanding credit-facility borrowings were $186.9 million, including $13.7 million current debt; $67.5 million remained available under the revolver. The facility matures in December 2023. ANI reported compliance with its financial covenants at year-end.
Material changes, outlook, and risks
- ANI acquired Amerigen’s U.S. portfolio of 23 generic products in January 2020 for $56.8 million, plus up to $25.0 million in contingent payments; no contingent payment was due for 2020. It launched ten products during the year.
- COVID-19 reduced prescription volumes and sales, particularly in the second quarter, amid fewer physician visits and elective procedures. Prescription volumes improved later in 2020 but had not returned to pre-pandemic levels. Manufacturing remained open, with minor supply-chain disruptions.
- The FDA issued a Refusal to File for the Cortrophin Gel supplemental NDA in April 2020. ANI was addressing filing gaps and anticipated resubmission in the second quarter of 2021. Management estimated 2021 Cortrophin pre-launch expenses of approximately $15–$20 million; approval and launch timing remain uncertain.
- After year-end, ANI agreed to acquire Novitium Pharma. Proposed consideration included an estimated $89.5 million cash payment, 2,466,667 ANI shares, and up to $46.5 million in earn-outs. The announced financing included a new $340 million secured credit facility and a $25 million preferred-stock PIPE investment. Closing was subject to conditions, including shareholder approval; completion was not assured.
- Key risks include customer concentration (three wholesalers represented 74% of 2020 revenue and about 81% of year-end receivables), generic price competition, dependence on single-source API suppliers, DEA quotas for controlled substances, and regulatory uncertainty over EEMT and Opium Tincture, which together generated $16.9 million, or about 8% of revenue.
- ANI disclosed litigation involving alleged EES marketing, Bystolic antitrust claims, and ranitidine-related claims, among other matters. The company stated it could not estimate potential losses for certain cases. The Yescarta royalty arrangement also faces litigation and disputed Israeli withholding-tax treatment, which could affect future cash receipts.
- Auditors issued an unqualified opinion on the financial statements and internal controls. Chargeback accrual estimates were identified as a critical audit matter; the year-end chargeback accrual was approximately $89 million.
Important facts for investors to verify
- Progress and FDA response to Cortrophin’s planned resubmission, including the ultimate launch timing and total pre-launch costs.
- Novitium transaction closing, final funding structure, resulting leverage, dilution, and integration performance.
- Whether operating cash generation recovers as acquisition spending and working-capital needs continue; year-end cash was substantially lower than in 2019.
- Product-level trends behind generic growth and branded declines, gross-margin pressure, inventory reserves, and customer concentration.
- Resolution of material litigation and royalty-related disputes, and any regulatory action concerning unapproved products or controlled substances.